| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 2.61 | -0.01 (-0.38%) | 1.63 - 4.50 | 255.8 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 2.59 |
|---|---|
| Previous Close | 2.62 |
| Day's Range | 2.50 - 2.63 |
| Market Cap | 261.7M |
| Avg Volume (10 Day) | 624.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.29 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Dyax Corp. Announces Participation in Upcoming Investor Events
Business Wire - Thursday 05/23/2013 8:00 AM ET
Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day – a Global Event to Raise Awareness of HAE
Business Wire - Thursday 05/16/2013 8:30 AM ET
Dyax Announces $30 Million Offering
Business Wire - Monday 05/13/2013 7:15 AM ET
Dyax Corp. to Participate in the Needham Healthcare Conference
Business Wire - Monday 04/29/2013 7:00 AM ET
Dyax Corp. Announces First Quarter 2013 Financial Results
Business Wire - Thursday 04/25/2013 4:01 PM ET
| DYAX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 6.13% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 4.74 |
| Company | Last | Change |
|---|---|---|
| Repligen Corp | 8.48 | -0.24% |
| Coronado Biosciences Inc | 9.56 | -0.62% |
| Xenoport Inc | 5.78 | +7.24% |
| Immunomedics Inc | 3.36 | +2.44% |
| BioTime Inc | 4.38 | +4.78% |
Data is delayed by at least 15 min.